Released: Monday 5th March 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Appointment of Dr. Stewart White as Acting CEO

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is about to enter what the Directors believe is an unprecedented period of growth. The Cramlington facilty will shortly come on line for non-GMP activities and we are working on a number of other projects. This means that we must re-structure our staff around the needs of the business and we expect to make a number of new appointments to augment our existing senior team.

As part of this re-structuring activity the Board is pleased to announce the appointment of Dr. Stewart White as Acting CEO following the decision of the COO, Mr. Gordon Sherriff to leave the Company. Dr. White was recruited into his present position as Commercial Director with a view to his progression to becoming CEO in due course. Stewart has made a significant impact on the business since joining Angel in December 2011 and the Board has every confidence in Stewart's ability to fulfill this new role and for the appointment to be made permanent after a period of evaluation.

Dr. Paul Harper, Executive Chairman, said: "Stewart has made an excellent start in his role at Angel, bringing drive, focus and leadership in his current role and more broadly across the business. During Gordon Sherriff's period of absence, Stewart has assumed a broad range of responsibilities alongside Lorna Peers, our FD, and myself. The senior staff have responded magnificently to the new challenges and greater responsibility supported by a steady stream of new appointments at both Pentlands and Cramlington."

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Commercial Director www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean / Elliot Berg +44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350

Media enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

Notes to Editors:

Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines and Healthcare products Regulatory Agency (MHRA).

Its customers range from early-stage biotechnology companies including ReNeuron plc and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.

Angel has two facilities: Pentlands Science Park near Edinburgh where it employs 38 people, and a site in Cramlington, near Newcastle-upon-Tyne, which is expected to be commissioned by the end of Q1 2012, initially employing up to 10 people.

More information is available at www.angelbio.com .

- Ends -